Drug Pricing & Patents
Drug Pricing & Patents
HIV Glasgow: New $90-$90-$90 Target Needed for Global Viral Hepatitis, HIV, and TB Treatment
- Details
- Category: Drug Pricing & Patents
- Published on Monday, 24 October 2016 00:00
- Written by Keith Alcorn
The costs of making drugs to treat viral hepatitis, HIV, and tuberculosis (TB) are now so low that each disease could be treated for less than $90, Andrew Hill of St. Stephen’s AIDS Trust said at the opening plenary of the International Congress of Drug Therapy in HIV Infection this week in Glasgow.
IAS 2015: The TPP and Access to HIV and HCV Treatment [VIDEO]
- Details
- Category: HIV Policy & Advocacy
- Published on Wednesday, 09 September 2015 00:00
- Written by Gregory Fowler
The Trans-Pacific Partnership trade agreement, now under consideration, will heavily impact the availability of medications for HIV and viral hepatitis, both in middle-income countries and in high-income countries such as Canada that rely on generic drugs, advocates said at a Médecins Sans Frontières media briefing at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.
UNAIDS: More than 7 Million Africans on HIV Treatment, Deaths Continue to Fall
- Details
- Category: HIV Treatment
- Published on Wednesday, 22 May 2013 00:00
- Written by UNAIDS
The number of people in Africa receiving antiretroviral medications increased from less than 1 million in 2005 to an estimated 7.1 million in 2012, according to a new report from UNAIDS. The report also notes that AIDS-related deaths and new HIV infections have both fallen by about 30% over the past decade. 
BHIVA 2015: HIV Treatment Outcomes No Better with Single-tablet Regimens than Individual Pills
- Details
- Category: Drug Pricing & Patents
- Published on Thursday, 23 April 2015 00:00
- Written by Roger Pebody
One-pill-a-day HIV treatments such as Atripla, Stribild, Complera, and Triumeq and Triumeq have the same rates of virological failure, drug resistance, and side effects as multiple tablet regimens, according to a meta-analysis presented to the British HIV Association (BHIVA) conference this week in Brighton. Single tablets cost the UK National Health Service (NHS) 5 five times more but have unproven clinical benefits, said Andrew Hill of Chelsea and Westminster Hospital.
HIV Medical Providers Call for Fair Drug Pricing to Expand Access to Treatment
- Details
- Category: HIV Treatment
- Published on Tuesday, 11 December 2012 00:00
- Written by Liz Highleyman
Practitioners from the American Academy of HIV Medicine (AAHIVM) and the HIV Medicine Association (HIVMA) delivered a joint statement to pharmaceutical company executives this week, asking the industry to reconsider its pricing for antiretroviral drugs so that more people in the U.S. and worldwide are able to access treatment. 
More Articles...
- DHHS Implements Common Application for HIV Patient Assistance Programs
- AIDS 2012: HIV Drugs Cheaper than Thought, Clinton Report Says
- Companies Lower HIV Drug Prices for ADAP, but Many Patients Still Waiting
- Medicines Patent Pool Licenses First HIV and HBV Drugs
- IAS 2011: Biomedical Prevention a Watershed, Global Access Remains Elusive
- FDA Grants Tentative Approval of Generic Fixed-dose Combination of Efavirenz/emtricitabine/tenofovir
Web Design and Development by